These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12619106)

  • 21. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
    Dong-Dong L; Xi-Ran Z
    Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1.
    Chen Ban K; Singh H; Krishnan R; Fong Seow H
    J Surg Oncol; 2004 Jun; 86(3):157-63. PubMed ID: 15170655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [p53 gene mutation in hepatocellular carcinoma].
    Jiang W; Lu Q; Pan G
    Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):531-2. PubMed ID: 11825456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.
    Gouas DA; Shi H; Hautefeuille AH; Ortiz-Cuaran SL; Legros PC; Szymanska KJ; Galy O; Egevad LA; Abedi-Ardekani B; Wiman KG; Hantz O; Caron de Fromentel C; Chemin IA; Hainaut PL
    Carcinogenesis; 2010 Aug; 31(8):1475-82. PubMed ID: 20538734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of hepatitis B virus X gene mutation in Hong Kong patients with hepatocellular carcinoma.
    Chen GG; Li MY; Ho RL; Chak EC; Lau WY; Lai PB
    J Clin Virol; 2005 Sep; 34(1):7-12. PubMed ID: 16087118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Characteristics of high frequency 249 codon mutation of p53 gene in hepatocellular carcinoma in prevalent area of China].
    Ming L; Yuan B; Thorgeirsson SS
    Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):122-4. PubMed ID: 11776852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular therapy and prevention of hepatocellular carcinoma.
    Blum HE
    Hepatobiliary Pancreat Dis Int; 2003 Feb; 2(1):11-22. PubMed ID: 14599923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis.
    Tannapfel A; Wittekind C
    Virchows Arch; 2002 Apr; 440(4):345-52. PubMed ID: 11956813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional inactivation but not structural mutation of p53 causes liver cancer.
    Ueda H; Ullrich SJ; Gangemi JD; Kappel CA; Ngo L; Feitelson MA; Jay G
    Nat Genet; 1995 Jan; 9(1):41-7. PubMed ID: 7704023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention.
    Wild CP; Montesano R
    Cancer Lett; 2009 Dec; 286(1):22-8. PubMed ID: 19345001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocellular carcinoma and the underlying mechanisms.
    Oyagbemi AA; Azeez OI; Saba AB
    Afr Health Sci; 2010 Mar; 10(1):93-8. PubMed ID: 20811532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan.
    Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S
    J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathogenesis of human hepatocellular carcinoma.
    Wang XW; Hussain SP; Huo TI; Wu CG; Forgues M; Hofseth LJ; Brechot C; Harris CC
    Toxicology; 2002 Dec; 181-182():43-7. PubMed ID: 12505283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between mutation on precore region of integrated HBV DNA and p53 gene mutation in hepatocellular carcinoma].
    Wang XH; Wang PL
    Ai Zheng; 2003 Jul; 22(7):715-8. PubMed ID: 12866962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
    Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
    Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 249ser p53 mutation in the serum of black southern African patients with hepatocellular carcinoma.
    Kimbi GC; Kew MC; Yu MC; Arakawa K; Hodkinson J
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1185-90. PubMed ID: 16048565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention.
    Anwar WA; Khaled HM; Amra HA; El-Nezami H; Loffredo CA
    Mutat Res; 2008; 659(1-2):176-84. PubMed ID: 18346933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatocellular carcinoma: molecular biology aspects].
    Blum HE
    Zentralbl Chir; 1994; 119(11):759-63. PubMed ID: 7846955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
    Hsu IC; Tokiwa T; Bennett W; Metcalf RA; Welsh JA; Sun T; Harris CC
    Carcinogenesis; 1993 May; 14(5):987-92. PubMed ID: 8389256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.